Introduction. There is growing concern about infections caused by non-albicans Candida species, including species of the Candida parapsilosis complex – which have seen a considerable increase in cases during the COVID-19 pandemic – in addition to concern about nematode resistance to currently used anthelmintics. Gap Statement. Lupeol is a triterpenoid phytosterol that has a wide range of biological activities, although its antifungal and antiparasitic potential is still poorly explored. Additionally, its effect on the biofilm of the C. parapsilosis species complex has not yet been studied. Aim. This study aimed to investigate the antifungal effect of lupeol against C. parapsilosis complex species, in planktonic cells and mature biofilms, as well as its nematicidal potential against Caenorhabditis elegans. In addition, molecular docking was performed to identify potential target molecules for lupeol’s antifungal effect. Methodology. Twelve strains of C. parapsilosis species complex were used. Planktonic susceptibility was performed through the broth microdilution assay, while the antibiofilm effect was investigated by measuring the biomass and metabolic activity. The antifungal mechanism of action of lupeol was investigated by target fishing. The evaluation of the nematicidal effect was performed using the C. elegans infection model. Results. Lupeol demonstrated antifungal activity against planktonic cells with a MIC between 64 and 512 µg ml−1. In mature biofilms, lupeol was able to reduce biomass starting from a concentration of 1024 µg ml−1 and reduce metabolic activity from a concentration of 64 µg ml−1. It was observed that there was interaction of lupeol with the enzyme 14α-demethylase. Furthermore, lupeol had a nematicidal effect from a concentration of 64 µg ml−1. Conclusion. Lupeol exhibits an antifungal effect on the C. parapsilosis species complex, in the planktonic and mature biofilm forms, possibly by affecting the ergosterol synthesis. Lupeol further demonstrated a nematicidal potential.
Histoplasmosis is a respiratory disease caused by Histoplasma capsulatum, a dimorphic fungus, with high mortality and morbidity rates, especially in immunocompromised patients. Considering the small existing therapeutic arsenal, new treatment approaches are still required. Chitosan, a linear polysaccharide obtained from partial chitin deacetylation, has anti-inflammatory, antimicrobial, biocompatibility, biodegradability, and non-toxicity properties. Chitosan with different deacetylation degrees and molecular weights has been explored as a potential agent against fungal pathogens. In this study, the chitosan antifungal activity against H. capsulatum was evaluated using the broth microdilution assay, obtaining minimum inhibitory concentrations (MIC) ranging from 32 to 128 µg/mL in the filamentous phase and 8 to 64 µg/mL in the yeast phase. Chitosan combined with classical antifungal drugs showed a synergic effect, reducing chitosan’s MICs by 32 times, demonstrating that there were no antagonistic interactions relating to any of the strains tested. A synergism between chitosan and amphotericin B or itraconazole was detected in the yeast-like form for all strains tested. For H. capsulatum biofilms, chitosan reduced biomass and metabolic activity by about 40% at 512 µg/mL. In conclusion, studying chitosan as a therapeutic strategy against Histoplasma capsulatum is promising, mainly considering its numerous possible applications, including its combination with other compounds.